Gastric and gastroesophageal cancer therapy reshapes around HER2 maturity and claudin18.2 entry
Trastuzumab deruxtecan in HER2-low gastric, claudin18.2-targeted zolbetuximab approval, and IO combinations are restructuring upper GI oncology.
Gastric and gastroesophageal junction cancer has been a HER2 plus chemotherapy story for years. Trastuzumab deruxtecan extends ADC reach into HER2-low disease, claudin18.2-targeted zolbetuximab brings a novel biomarker-defined option, and IO plus chemotherapy is now standard first-line in selected populations. The biomarker-pathway investment (HER2, claudin18.2, MSI status, PD-L1 CPS) is now layered, and the testing-rate trajectory defines the addressable-population reach.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- SnapshotAdult diffuse glioma therapy reference (2026)
- ExplainedWhat is glioblastoma?